Online Program

Return to main conference page

All Times EDT

Thursday, September 23
Thu, Sep 23, 3:00 PM - 4:15 PM
Virtual
Novel Applications of the Win Ratio in COVID-19: Diseases with Heterogeneous Clinical Manifestations or Diseases with Benefit in Multiple Domains

Assess Impact of Subgroup Effect in Heterogenous Disease via Win Ratio Analysis (302439)

Margaret Gamalo, Pfizer Inc. 
*Ran Liao, Eli Lilly and Company 

Keywords: Win ratio, Composite endpoint, Survival analysis, Subgroup, Heterogenous

In clinical studies, it is common to encounter a situation where the treatment effect is influenced by different subgroups defined by a specific baseline demographic or clinical characteristics. These subgroups characterize the heterogeneity of the disease and particularly its impact the endpoint of interest. For example, it was known that mortality (time to death) and disease progression of COVID-19 and cardiovascular disease varies between gender and age group (ref). Similarly, the recovery (time to recovery) in varies between milder symptoms group compared to the severe symptoms group. These observations create challenges in choosing the time-to-event endpoint and in making a reasonable assumption for sample size estimation. Furthermore, it may complicate the analysis method due to non-proportionality of the underlying hazard. In such cases, a composite endpoint could be considered which can provide a higher event rate and more statistical power resulting in smaller sample size and shorter study duration. Win ratio is a non-parametric methodology that allows handling of composite endpoint with consideration of the clinical importance of the endpoints. In this research work, we will evaluate the subgroup effect and its impact to analysis of study result. Both unmatched and matched pair win ratio approach will be explored to compare to clinical logrank test and Cox proportional model. The empirical power and type I error rate will be reported to compare each method.